News

Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments

Sep 10, 2026 | News, Regulatory

MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain

Gilead opens new research centre bringing together oncology, inflammation and research data science teams

Sep 9, 2026 | News, Healthcare

The centre in California supports the company’s $32bn US investment

AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer

Sep 8, 2026 | News, Regulatory

The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression

FDA approves Priovant’s Lisraya for dermatomyositis

Sep 7, 2026 | News, Regulatory

This is the first oral drug treatment for this rare disease in adults

Moderna’s updated COVID-19 mRNA vaccine approved by MHRA

Sep 4, 2026 | News, Regulatory

The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme

Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA

Sep 4, 2026 | News, Regulatory

The 2026-2027 vaccine targets the XFG variant to more closely match current variants

Novartis announces trial results for remibrutinib in relapsing multiple sclerosis

Sep 3, 2026 | News, Research

MS affects nearly three million people worldwide and has three main types

Lilly to acquire Merida Biosciences in deal worth up to $2.875bn

Sep 2, 2026 | News, Sales

The acquisition is to advance treatments for serious autoimmune and allergic diseases

AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer

Sep 1, 2026 | News, Regulatory

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

Genentech’s US manufacturing facility advances with construction milestone

Aug 28, 2026 | News, Healthcare

The facility is part of Roche and Genentech’s broader $50bn commitment to US R&D and manufacturing infrastructure

FDA approves Revolution Medicines’ first in class targeted therapy for metastatic pancreatic cancer

Aug 27, 2026 | News, Regulatory

67,000 new cases of pancreatic cancer are diagnosed in the US each year

BriaCell advances personalised skin cancer immunotherapy vaccine candidate

Aug 26, 2026 | News, Research

Around 112,000 new cases of skin cancer will be diagnosed in the US in 2026

Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments

Gilead opens new research centre bringing together oncology, inflammation and research data science teams

AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer

FDA approves Priovant’s Lisraya for dermatomyositis

Moderna’s updated COVID-19 mRNA vaccine approved by MHRA

Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA

Novartis announces trial results for remibrutinib in relapsing multiple sclerosis

Lilly to acquire Merida Biosciences in deal worth up to $2.875bn

AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer

Genentech’s US manufacturing facility advances with construction milestone

FDA approves Revolution Medicines’ first in class targeted therapy for metastatic pancreatic cancer

BriaCell advances personalised skin cancer immunotherapy vaccine candidate

Latest content

Latest intelligence

Quick links